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Abstract Schimke immunoosseous dysplasia (SIOD) is an
autosomal recessive multisystem disorder characterized by
prominent spondyloepiphyseal dysplasia, T cell deficiency,
and focal segmental glomerulosclerosis. Biallelic mutations
in swi/snf-related, matrix-associated, actin-dependent regu-
lator of chromatin, subfamily a-like 1 (SMARCAL1) are the
only identified cause of SIOD, but approximately half of
patients referred for molecular studies do not have
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DOI 10.1007/s00431-009-1115-9detectable mutations in SMARCAL1. We hypothesized that
skeletal features distinguish between those with or without
SMARCAL1 mutations. Therefore, we analyzed the skeletal
radiographs of 22 patients with and 11 without detectable
SMARCAL1 mutations. We found that patients with
SMARCAL1 mutations have a spondyloepiphyseal dysplasia
(SED) essentially limited to the spine, pelvis, capital femoral
epiphyses, and possibly the sella turcica, whereas the hands
and other long bones are basically normal. Additionally, we
found that several of the adolescent and young adult patients
developed osteoporosis and coxarthrosis. Of the 11 patients
without detectable SMARCAL1 mutations, seven had a SED
indistinguishable from patients with SMARCAL1 mutations.
We conclude therefore that SED is a feature of patients with
SMARCAL1 mutations and that skeletal features do not distin-
guish who of those with SED have SMARCAL1 mutations.
Keywords Genocopy.Immunodeficiency.Proteinuria.
Skeletaldysplasia.Locusheterogeneity.Schimke
immunoosseousdysplasia
Abbreviations
DNA Deoxyribonucleic acid
mRNA Messenger ribonucleic acid
SD Schimke immunoosseous dysplasia database
SED Spondyloepiphyseal dysplasia
SIOD Schimke immunoosseous dysplasia
SMARCAL1 swi/snf-related, matrix-associated, actin-
dependent regulator of chromatin, subfamily
a-like 1
SNF2 Sucrose nonfermenting type 2
TIA Transient ischemic attack
Introduction
The osteochondrodysplasias are a heterogeneous group of
inherited disorders of skeletal growth and development
[28]. Among these, the spondyloepiphyseal dysplasias
(SEDs) are characterized by primary involvement of the
vertebrae and proximal epiphyseal centers resulting in a
short-trunk disproportionate dwarfism [16, 26]. The radio-
graphic findings, which are frequently age dependent,
commonly include flattened vertebrae (platyspondyly) and
dysplastic femoral epiphyses.
Schimke immunoosseous dysplasia (SIOD; OMIM
#242900) is an autosomal recessive, pleiotropic disorder
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skeletal manifestations include mild facial anomalies [3,
23], T cell immunodeficiency [3, 27], nephrotic syndrome
[3, 10, 11, 24, 27], hypothyroidism [3], migraine-like
headaches [15], cerebral ischemia [10, 25], and enteropathy
[13, 14, 17, 18].
SIOD is caused by biallelic loss-of-function muta-
tions in SMARCAL1 (OMIM #606622) [4]. SMARCAL1
encodes a protein homologous to the sucrose nonferment-
ing type 2 family of chromatin-remodeling proteins [8,
19]; it functions as a DNA annealing helicase [30].
However, in our experience, nearly half of patients with
manifestations of SIOD do not have identifiable mutations
in the coding exons of SMARCAL1 or detectable alter-
ations of SMARCAL1 mRNA or protein [7] suggesting a
close phenotypic overlap with other conditions or genetic
heterogeneity.
Despite the clinical similarity of these patients, we
hypothesized that individuals with and without SMARCAL1
mutations are distinguishable by the type of bone dysplasia.
Therefore, we analyzed detailed clinical and radiographic
information from a series of 33 SIOD patients with or
without detectable SMARCAL1 mutations.
Materials and methods
Human subjects
Patients referred to this study gave informed consent
approved by the Institutional Review Board of the Hospital
for Sick Children (Toronto, ON, Canada), Baylor College
of Medicine (Houston, TX, USA), or the University of
British Columbia (Vancouver, BC, Canada).
Features SIOD patients with
SMARCAL1 mutations
affected/total
SIOD patients without
SMARCAL1 mutations
affected/total
Fisher’s exact
test (p)
Dysmorphism
Hair hypoplasia 11/20 5/11 0.45
Broad low nasal bridge 12/21 7/11 0.51
Bulbous nasal tip 14/21 6/10 0.29
Hyperpigmented macules 14/20 6/11 0.89
Protuberant abdomen 15/21 9/10 0.25
Elongated upper lip 8/19 3/8 0.59
Development
Delayed development 6/22 5/10 0.15
Schooling delay 4/11 3/7 0.78
Endocrine
Serologic hypothyroidism 9/19 4/9 0.60
Hematology and immunology
Lymphopenia 15/21 8/10 0.48
Recurrent infections 9/22 6/11 0.35
Neutropenia 4/18 5/11 0.18
Anemia 10/21 6/11 0.50
Thrombocytopenia 3/20 3/11 0.26
Nephrology
Hypertension 18/21 9/10 0.61
Nephrotic syndrome 22/22 9/11 0.10
Progressive renal failure 13/20 8/11 0.49
Proteinuria 22/22 10/10 1.0
Dialysis or graft 13/22 6/10 0.64
Neurology
TIAs 9/22 3/10 0.43
Strokes 7/22 3/11 0.56
Migraine-like headaches 8/17 1/6 0.21
Skeletal radiographic findings
SED 22/22 7/11 0.01
Table 1 Features of SIOD
patients with and without
SMARCAL1 mutations
SED spondyloepiphyseal
dysplasia, TIA transient
ischemic attack
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The clinical data for patients were obtained from question-
naires completed by the referring physician as well as
medical records and summaries provided by that physician.
The data obtained for patients with and without SMAR-
CAL1 mutations were tabulated and then summed to allow
comparison of the features of patients in each group. If a
feature was not reported for a patient, then that patient was
excluded from the denominator. Statistically significant
differences between the groups were determined by the
Fisher’s exact test. Also, to subgroup patients according to
disease severity, each patient’s signs and symptoms were
scored as previously described [12].
Analysis of skeletal radiographs
All radiographs were reviewed independently by Jürgen
Spranger and Cornelius F. Boerkoel.
Results
Since we had previously found that only about half of patients
clinically diagnosed with SIOD have detectable SMARCAL1
mutations, we sought to identify skeletal radiographic features
distinguishingthesetwogroupsofpatients[7]. Identification of
such features would be useful for guiding molecular diagnosis
as well as for characterization of other genetic causes of
SIOD. To this end, we assembled detailed clinical and skeletal
radiographic data on 33 patients, 11 without SMARCAL1
mutations and 22 with biallelic SMARCAL1 mutations.
Phenotypic comparisons
The 22 patients with and 11 without detectable SMARCAL1
mutations have very similar clinical features (Table 1;
Supplementary Tables 1 and 2) and similar disease severity
scores, which we calculated as previously described [7].
Those with SMARCAL1 mutations have slightly more
neurological complications, but these are insufficient to
distinguish between the two groups of patients. Given the
inadequacy of clinical features for distinguishing those with
and without SMARCAL1 mutations, we looked for distin-
guishing radiographic features.
Radiographic findings
As previously described [26], the spondyloepiphyseal
dysplasia of SIOD is most prominent in the spine, pelvis,
Fig. 1 Typical bony features of
SIOD. a Lateral spine radiograph
of a 5-year-old child showing
dorsally flattened, pear-shaped
vertebral bodies. b Lateral skull
radiograph of a 5-year-old child
showing the typical widening of
the sella. c Posteroanterior hand
radiograph of a 13-year-old
adolescent showing the absence
of bony abnormalities. d
Anteroposterior hip radiograph
of a 4-year-old child showing the
small, laterally displaced capital
femoral epiphyses, hypoplastic
basilar ilia, and upslanting and
poorly formed acetabula
804 Eur J Pediatr (2010) 169:801–811and capital femoral epiphyses (Fig. 1). The hands and other
long bones are essentially normal.
Spine findings among patients with SMARCAL1 mutations
The vertebral bodies are ovoid, dorsally flattened and
without segmentation defects at all ages (Figs. 2 and 3).
The spinal changes between 4 and 6 years of age show
dorsally flattened, pear-shaped vertebral bodies. By 7–
11 years of age, there is more generalized vertebral
flattening with slightly irregular upper and lower plates
(see SD114, Fig. 2). There is variable expressivity as only
mild abnormalities are observed in some patients (see
SD112, Fig. 2). By adulthood, all have clear signs of
progressive osteopenia with compressed vertebral bodies
and vertebral bone density similar to that of the soft tissue
(Figs. 1 and 2). Peculiarly, SD27 also has diffuse
calcification of her discs (Figs. 2 and 3).
Pelvisandcapitalfemoralepiphysealfindingsamongpatients
with SMARCAL1 mutations
Nearly consistently at all ages, the pelvis and femora are
notable for small, laterally displaced capital femoral
Fig. 2 Lateral spine radiographs of patients with identified SMAR-
CAL1 mutations at different ages. The vertebral bodies are flattened at
all ages and pear-shaped between 4 and 6 years. There is generalized
vertebral flattening with slightly irregular upper and lower plates in
some patients. The severity of the vertebral changes is variable as
illustrated by comparison of SD112 with SD66. Note the radiolucency
of adult vertebrae consistent with the progressive osteopenia of SIOD
patients. SD27 had diffuse disc calcification; the significance of this is
uncertain
Eur J Pediatr (2010) 169:801–811 805epiphyses, hypoplastic basilar ilia with upslanting and
poorly formed acetabula (Fig. 4). The femoral dysplasia
progresses to premature coxarthrosis requiring prosthetic
therapy (SD27, Fig. 4).
The severity of these skeletal changes varies among the
patients. For example, the proximal femoral pathology
ranges from coxa valga with well-preserved capital femoral
epiphyses and a normal pelvis (SD78, Fig. 4) to short
femoral necks with a peculiar lip-like medial protrusion and
markedly hypoplastic lower ilia (SD121, Fig. 4).
Skull findings among patients with SMARCAL1 mutations
No bony abnormalities have been reported in the skull of
SIOD patients before. However, of five skull radiographs,
three (SD44, SD61, SD114) show a markedly wide sella
turcica, one (SD120) a depression of the anterior portion of
the sella, and one (SD79) a normal sella turcica (Fig. 5).
Hand and feet findings among patients with SMARCAL1
mutations
Although one SIOD individual has been referred to us with
preaxial hexadactyly (C. F. Boerkoel, unpublished data), no
others have been reported with bony abnormalities of the
hands or feet [26]. Consistent with this, the hand and feet
radiographs from the patients in this study do not show
bony abnormalities (Fig. 5).
Skeletal findings among patients without detectable
SMARCAL1 mutations
Among the patients without detectable SMARCAL1 muta-
tions, three (SD87, SD95, SD55) have skeletal abnormalities
typical of SIOD (Fig. 6). Two (SD80, SD85) have a mild
spondyloepiphyseal dysplasia consistent with SIOD (Fig. 6),
similar to that of patient SD112 (Figs. 2, 3,a n d4). One
(SD54) has a typical SIOD-type spondyloepiphyseal dyspla-
sia and severe scoliosis and anterior hypoplasia of L2; these
latter changes, which have not been observed among SIOD
patients with a SMARCAL1 mutation, may be secondary to
an unrelated muscular hypotonia.
Patients distinct from SIOD
Radiographs from four patients diagnosed with SIOD but
without a detectable SMARCAL1 mutation do not show the
Fig. 3 Anterior–posterior spine radiographs of patients with identified SMARCAL1 mutations at different ages show various degrees of
platyspondyly. SD27 had diffuse disc calcification; the significance of this is uncertain
Fig. 4 Hip radiographs of patients with identified SMARCAL1
mutations at different ages. The femora generally have small, laterally
displaced capital epiphyses, but normal epiphyseal ossification may
occur (e.g., SD78, SD 112). By adulthood, the femoral dysplasia
usually progresses to premature coxarthrosis (SD18 and SD27)
requiring prosthetic therapy (SD27). The ilia are usually small because
of hypoplastic basilar portions and have upslanting and poorly formed
acetabula. The severity of the ilia and femoral changes is variable as
illustrated by comparison of SD78, who had preserved capital femoral
epiphyses and a normal pelvis, with SD121, who had short femoral
necks with a peculiar lip-like medial protrusion and markedly
hypoplastic basilar ilia
b
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one (SD89) show enchondromata in the tubular and flat
bones and flattened vertebral bodies with irregular areas of
increased and decreased mineralization (data not shown);
these findings are most consistent with a form of
spondyloenchondrodysplasia [21]. The radiographs from
three (SD81, SD52a, SD52b) have no signs of SED.
Discussion
T h ec h a r a c t e r i s t i cs k e l e t a lf e a t u r e so fS I O Dp a t i e n t sw i t h
SMARCAL1 mutations are (1) ovoid and flattened vertebral
bodies without segmentation defects, (2) small, laterally
displaced capital femoral epiphyses, hypoplastic basilar ilia,
and upslanting and poorly formed acetabula, and (3) possibly
a wide sella. The flattening of the vertebrae and the
abnormalities of the hips usually worsen with age and do
so to a degree independent of the severity of other features of
SIOD. Also, during later childhood, adolescence, and early
adulthood, many individuals with SIOD develop coxarth-
rosis and vertebral osteopenia.
A wide sella turcica has not been reported among SIOD
patients previously. If additional studies confirm the
findings in this small number of patients, then this will be
an additional marker for the clinical diagnosis of SIOD.
The wide sella turcica does not reflect anterior pituitary or
adenohypophysis dysfunction since in the three patients
tested, all had normal growth hormone and thyroid
stimulating hormone levels. Also, prior reviews of anterior
pituitary function in SIOD patients have not identified a
functional pituitary defect [3].
One reason the wide sella turcica may not have been
noted previously is the high degree of intra- and interfa-
milial variability of SIOD [2, 7]. This is reinforced by our
findings that not all SIOD patients with SMARCAL1
mutations had each of the typical skeletal findings.
Additionally, we found that there was even variability
among tissues within the same person since the severity of
vertebral flattening did not predict the severity of hip
dysplasia or vice versa.
Relevant to our question of whether the clinical skeletal
radiographs can guide molecular testing, our results show
that none of the patients without SED had detectable
SMARCAL1 mutations. Therefore, testing for SMARCAL1
mutations in this group may not be indicated although
studies with more patients are needed to confirm this. On
the other hand, for individuals with radiographic findings of
SED, there were no distinguishing radiographic or clinical
features to suggest who would or would not have detectable
Fig. 5 Skull and hand radiographs of patients with identified SMARCAL1 mutations at different ages. Note the marked widening of the sella in
SD44, SD61, and SD79 and mild widening of the sella in SD120. No bony abnormalities are observed in the hands
808 Eur J Pediatr (2010) 169:801–811SMARCAL1 mutations. Therefore, all patients with SED
and the other clinical signs of SIOD should be tested for
SMARCAL1 mutations.
The known molecular mechanism underlying SIOD is a
generalized disturbance of genomic structure arising sec-
ondary to loss of SMARCAL1 DNA strand annealing [31].
This disturbance disrupts both DNA replication [1, 6, 9, 20,
29, 31] and RNA transcription (Baradaran-Heravi et al.,
submitted for publication; Morimoto et al., submitted for
publication). Since cell proliferation and RNA transcription
are quantitative traits affected by environment, stochastics,
and genetic background [5, 22], the variability among
patients and tissues can be accounted for by the combined
impact of environment, stochastics, and genetic variation.
The similar clinical and radiographic features of indi-
viduals with and without SMARCAL1 mutations also
Fig. 6 Lateral spine and hip radiographs of SIOD patients without
detectable SMARCAL1 mutations at different ages. Note the similarity
of bony features to those with SMARCAL1 mutations. SD54 had
kyphoscoliosis and anterior hypoplasia of L2, which may have been
secondary to an unrelated muscular hypotonia
Eur J Pediatr (2010) 169:801–811 809suggest that SIOD could be induced by some environmen-
tal conditions or by mutations in genes other than
SMARCAL1. Evidence supporting genetic heterogeneity as
opposed to environmental factors includes the recurrence of
disease in siblings, the absence of disease in parents, and
the geographic dispersal of patients. Of interest for human
biology, this suggests that although SMARCAL1 is the
only identified annealing helicase in humans [30], other
enzymes with redundant or similar function may exist or
that SMARCAL1 deficiency mimics that of another global
modulator of chromatin structure. Assessments of these
possibilities as well as delineation of the physiologic
mechanism leading to the skeletal abnormalities will
require studies in model organisms.
Besides being unable to distinguish SIOD patients with
and without SMARCAL1 mutations, skeletal radiographs
also do not differentiate SIOD from many other spondy-
loepiphyseal dysplasias. The differential diagnosis of SIOD
includes other forms of spondyloepiphyseal and spondy-
loepimetaphyseal dysplasia listed in group 11 of the Interna-
tional Nosology [28]. These are distinguished from SIOD by
their different clinical presentation and by the absence of the
characteristic extraskeletal features such as facial dysmor-
phism, skin changes, T cell deficiency, and renal failure.
Thus, the skeletal features are not pathognomonic of SIOD.
In summary, we further define the radiographic features of
SIOD and show that SED is a feature common to all
individuals with SIOD and SMARCAL1 mutations. However,
among SIOD patients with SED, no radiographic features
distinguish those with SMARCAL1 mutations from those
without SMARCAL1 mutations. Understanding of the clinical
variability of this disorder as well as other possible genetic
causes requires further elucidation of the molecular mecha-
nisms underlying SIOD.
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